| Ytd | -72.46% | |
| 1y | -80.42% |
| Open | 0.33 | Prev Close | 0.32 | Low | 0.32 | High | 0.33 | Mkt Cap | 2.90M |
| Vol | 18.53K | Avg Vol | 10.34M | EPS | -1.19 | P/E | -0.27 | Forward P/E | -0.90 |
| Beta | 0.73 | Short Ratio | 1.95 | Inst. Own | 13.74% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.33 | 200-d Avg | 0.73 | 1yr Est | 13.00 |
BRTX News
https://ir.biorestorative.com/sec-filings/all-sec-filings/content/0001493152-26-033593/form8-k.htm
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-mark
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company")
MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,”
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development
US stocks mixed, Dow up 300 pts. Dow up 0.64%, NASDAQ down 0.34%. Consumer discretionary up 1.7%, en
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all sharehol
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment admi
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optim
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.19 per share versus the Z
Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patie
Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as ind
Collaboration establishes an independent clinical validation pathway, expands access to influential
Partnership to drive brand architecture, go-to-market execution, and global launch of the Company's
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No a
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.32 per share versus the Z
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerabili
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA,
Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical
BioRestorative Therapies, Inc. (OTCMKTS:BRTX - Get Free Report) crossed below its 50-day moving aver
MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,
Stocks That Hit 52-Week Lows On Tuesday